Evidence map›Paper›PMID 27789416›Full record

ArticleBone2017

Compound heterozygous variants in NBAS as a cause of atypical osteogenesis imperfecta.

M Balasubramanian, J Hurst, S Brown, N J Bishop, P Arundel, C DeVile, R C Pollitt, L Crooks, D Longman, J F Caceres and 9 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in Bone, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Article
  3. Hepatic Phenotype in NBAS-Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Observational
  4. [Clinical features and genetic study of four cases of pediatric acute liver failure caused byZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  5. A novel splicing variant inFrontiers in genetics · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Membrane trafficking in health and disease.Disease models & mechanisms · 2020
    Review
  17. Defining clinical subgroups and genotype-phenotype correlations in NBAS-associated disease across 110 patients.Genetics in medicine : official journal of the American College of Medical Genetics · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

M BalasubramanianSheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, UK; Highly Specialised Service for Severe, Complex and Atypical OI, UK. Electronic address: meena.balasubramanian@nhs.net.
J HurstNE Thames Clinical Genetics Service, Great Ormond Street Hospital, UK.
S BrownSheffield RNAi Screening Facility, Department of Biomedical Sciences, University of Sheffield, UK.
N J BishopHighly Specialised Service for Severe, Complex and Atypical OI, UK; Academic Unit of Child Health, University of Sheffield, UK.
P ArundelHighly Specialised Service for Severe, Complex and Atypical OI, UK.
C DeVileHighly Specialised Service for Severe, Complex and Atypical OI, UK.
R C PollittAcademic Unit of Child Health, University of Sheffield, UK; Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, UK.
L CrooksSheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, UK; Department of Biosciences and Chemistry, Sheffield Hallam University, UK.
D LongmanMRC Human Genetics Unit, IGMM, University of Edinburgh, UK.
J F CaceresMRC Human Genetics Unit, IGMM, University of Edinburgh, UK.
F ShackleyDepartment of Paediatric Immunology, Sheffield Children's NHS Foundation Trust, UK.
S ConnollyDepartment of Paediatric Hepatology, Sheffield Children's NHS Foundation Trust, UK.
J H PayneDepartment of Paediatric Haematology, Sheffield Children's NHS Foundation Trust, UK.
A C OffiahHighly Specialised Service for Severe, Complex and Atypical OI, UK; Academic Unit of Child Health, University of Sheffield, UK.
D HughesDepartment of Histopathology, Sheffield Teaching Hospitals NHS Foundation Trust, UK.
DDD StudyDDD Study, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
M J ParkerSheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, UK.
W HideCentre for Computational Biology, Sheffield Institute of Translational Neuroscience, University of Sheffield, UK.
T M SkerryMellanby Bone Research Centre, Department of Oncology & Metabolism, University of Sheffield, UK.
Sheffield Children's NHS Foundation Trust · GBUniversity of Sheffield · GBInstitute of Genetics and Cancer · GBPublic Health England · GBGreat Ormond Street Hospital · GBSheffield Teaching Hospitals NHS Foundation Trust · GB

Funding

Department of Health UKMedical Research Council MC_PC_15018Medical Research Council MC_PC_U127584479Wellcome TrustWellcome Trust WT098051
6 · The paper itself

Abstract

backgroundOsteogenesis imperfecta (OI), the commonest inherited bone fragility disorder, affects 1 in 15,000 live births resulting in frequent fractures and reduced mobility, with significant impact on quality of life. Early diagnosis is important, as therapeutic advances can lead to improved clinical outcome and patient benefit. REPORT: Whole exome sequencing in patients with OI identified, in two patients with a multi-system phenotype, compound heterozygous variants in NBAS (neuroblastoma amplified sequence). Patient 1: NBAS c.5741G>A p.(Arg1914His); c.3010C>T p.(Arg1004*) in a 10-year old boy with significant short stature, bone fragility requiring treatment with bisphosphonates, developmental delay and immunodeficiency. Patient 2: NBAS c.5741G>A p.(Arg1914His); c.2032C>T p.(Gln678*) in a 5-year old boy with similar presenting features, bone fragility, mild developmental delay, abnormal liver function tests and immunodeficiency. DISCUSSION: Homozygous missense NBAS variants cause SOPH syndrome (short stature; optic atrophy; Pelger-Huet anomaly), the same missense variant was found in our patients on one allele and a nonsense variant in the other allele. Recent literature suggests a multi-system phenotype. In this study, patient fibroblasts have shown reduced collagen expression, compared to control cells and RNAseq studies, in bone cells show that NBAS is expressed in osteoblasts and osteocytes of rodents and primates. These findings provide proof-of-concept that NBAS mutations have mechanistic effects in bone, and that NBAS variants are a novel cause of bone fragility, which is distinguishable from 'Classical' OI.

conclusionsHere we report on variants in NBAS, as a cause of bone fragility in humans, and expand the phenotypic spectrum associated with NBAS. We explore the mechanism underlying NBAS and the striking skeletal phenotype in our patients.

Indexed as

Base SequenceCells, CulturedChildChild, PreschoolFibroblastsHeterozygoteHumansInfantInfant, NewbornMaleMutationNeoplasm ProteinsOsteogenesis ImperfectaProtein DomainsSkinNBAS protein, humanNeoplasm ProteinsBoneCollagen expressionFragilityNBASNonsense mediated decay (NMD)Osteogenesis imperfectaSecretory pathway

Identifiers

PMID27789416
PMCPMC6067660
OpenAlexW2540229854

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.